Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.

Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin L.

J Pharmacol Exp Ther. 2019 Aug 14. pii: jpet.119.258699. doi: 10.1124/jpet.119.258699. [Epub ahead of print]

2.

Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2.

Hankosky ER, Joolakanti SR, Nickell JR, Janganati V, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2017 Dec 15;27(24):5467-5472. doi: 10.1016/j.bmcl.2017.10.039. Epub 2017 Oct 20.

3.

GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.

Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP.

Eur J Pharmacol. 2017 Jan 15;795:143-149. doi: 10.1016/j.ejphar.2016.12.016. Epub 2016 Dec 13.

PMID:
27986625
4.

Bis(N-amidinohydrazones) and N-(amidino)-N'-aryl-bishydrazones: New classes of antibacterial/antifungal agents.

Shrestha SK, Kril LM, Green KD, Kwiatkowski S, Sviripa VM, Nickell JR, Dwoskin LP, Watt DS, Garneau-Tsodikova S.

Bioorg Med Chem. 2017 Jan 1;25(1):58-66. doi: 10.1016/j.bmc.2016.10.009. Epub 2016 Oct 10.

5.

Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2.

Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2016 Sep 15;26(18):4441-4445. doi: 10.1016/j.bmcl.2016.08.001. Epub 2016 Aug 2.

6.

Toward isolating the role of dopamine in the acquisition of incentive salience attribution.

Chow JJ, Nickell JR, Darna M, Beckmann JS.

Neuropharmacology. 2016 Oct;109:320-331. doi: 10.1016/j.neuropharm.2016.06.028. Epub 2016 Jun 28.

7.

1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2.

Nickell JR, Culver JP, Janganati V, Zheng G, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):2997-3000. doi: 10.1016/j.bmcl.2016.05.025. Epub 2016 May 10.

8.

Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.

Joolakanti SR, Nickell JR, Janganati V, Zheng G, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2016 May 15;26(10):2422-2427. doi: 10.1016/j.bmcl.2016.03.119. Epub 2016 Apr 1.

9.

Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.

Sviripa VM, Burikhanov R, Obiero JM, Yuan Y, Nickell JR, Dwoskin LP, Zhan CG, Liu C, Tsodikov OV, Rangnekar VM, Watt DS.

Org Biomol Chem. 2016 Jan 7;14(1):74-84. doi: 10.1039/c5ob01980j.

10.

Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.

Ding D, Nickell JR, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2015 Jul 1;25(13):2613-6. doi: 10.1016/j.bmcl.2015.04.105. Epub 2015 May 9.

11.

2',6'-Dihalostyrylanilines, pyridines, and pyrimidines for the inhibition of the catalytic subunit of methionine S-adenosyltransferase-2.

Sviripa VM, Zhang W, Balia AG, Tsodikov OV, Nickell JR, Gizard F, Yu T, Lee EY, Dwoskin LP, Liu C, Watt DS.

J Med Chem. 2014 Jul 24;57(14):6083-91. doi: 10.1021/jm5004864. Epub 2014 Jul 9.

12.

The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP.

Adv Pharmacol. 2014;69:71-106. doi: 10.1016/B978-0-12-420118-7.00002-0. Review.

13.

Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake.

Ding D, Nickell JR, Deaciuc AG, Penthala NR, Dwoskin LP, Crooks PA.

Bioorg Med Chem. 2013 Nov 1;21(21):6771-7. doi: 10.1016/j.bmc.2013.08.001. Epub 2013 Aug 11.

14.

GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.

Horton DB, Nickell JR, Zheng G, Crooks PA, Dwoskin LP.

J Neurochem. 2013 Oct;127(2):177-86. doi: 10.1111/jnc.12371. Epub 2013 Aug 19.

15.

Potential therapeutic uses of mecamylamine and its stereoisomers.

Nickell JR, Grinevich VP, Siripurapu KB, Smith AM, Dwoskin LP.

Pharmacol Biochem Behav. 2013 Jul;108:28-43. doi: 10.1016/j.pbb.2013.04.005. Epub 2013 Apr 18. Review.

16.

Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2).

Penthala NR, Ponugoti PR, Nickell JR, Deaciuc AG, Dwoskin LP, Crooks PA.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3342-5. doi: 10.1016/j.bmcl.2013.03.092. Epub 2013 Apr 2.

17.

Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.

Zheng G, Horton DB, Penthala NR, Nickell JR, Culver JP, Deaciuc AG, Dwoskin LP, Crooks PA.

Medchemcomm. 2013 Mar;4(3):564-568.

18.

Anesthesia case of the month. Administration of aged packed RBCs.

Nickell JR, Shih A.

J Am Vet Med Assoc. 2011 Dec 1;239(11):1429-31. doi: 10.2460/javma.239.11.1429. No abstract available.

PMID:
22087716
19.

Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.

Meyer AC, Horton DB, Neugebauer NM, Wooters TE, Nickell JR, Dwoskin LP, Bardo MT.

Neuropharmacology. 2011 Sep;61(4):849-56. doi: 10.1016/j.neuropharm.2011.05.033. Epub 2011 Jun 12.

20.

Second-by-Second Measures of L-Glutamate and Other Neurotransmitters Using Enzyme-Based Microelectrode Arrays.

Hascup KN, Rutherford EC, Quintero JE, Day BK, Nickell JR, Pomerleau F, Huettl P, Burmeister JJ, Gerhardt GA.

In: Michael AC, Borland LM, editors. Electrochemical Methods for Neuroscience. Boca Raton (FL): CRC Press/Taylor & Francis; 2007. Chapter 19.

21.

Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Nickell JR, Zheng G, Deaciuc AG, Crooks PA, Dwoskin LP.

J Pharmacol Exp Ther. 2011 Mar;336(3):724-33. doi: 10.1124/jpet.110.172882. Epub 2010 Sep 28.

22.

The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.

Beckmann JS, Siripurapu KB, Nickell JR, Horton DB, Denehy ED, Vartak A, Crooks PA, Dwoskin LP, Bardo MT.

J Pharmacol Exp Ther. 2010 Dec;335(3):841-51. doi: 10.1124/jpet.110.172742. Epub 2010 Aug 30.

23.

Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.

Nickell JR, Krishnamurthy S, Norrholm S, Deaciuc G, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP.

J Pharmacol Exp Ther. 2010 Feb;332(2):612-21. doi: 10.1124/jpet.109.160275. Epub 2009 Oct 23.

24.

Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).

Vartak AP, Nickell JR, Chagkutip J, Dwoskin LP, Crooks PA.

J Med Chem. 2009 Dec 10;52(23):7878-82. doi: 10.1021/jm900770h.

Supplemental Content

Loading ...
Support Center